Plasma protein treatment is extensively used to treat well-defined medical conditions, replacing missing or deficient proteins found in plasma, to allow their recipients to lead healthier and more productive lives. The patient populations that rely upon plasma protein therapies generally require regular infusions or injections for the duration of their lives. Plasma proteins therapies are significantly utilised in replacement therapies for the treatment of conditions, like deficiency of a coagulation factor in the field of hemostasis. coagulation factor deficiency can be genetic or can occur due to autoimmune disorder. It can also occur as a complication of cancer. Fibrinogen is extensively used as a replacement therapy for treatment of hemorrhagic diathesis in diseases, for instance dysfibrinogenemia, afibrinogenemia, and hypofibrinogenemia.
The plasma protein therapeutics market is principally driven by growing prevalence of immune deficiency disorders, autoimmune disorders, neurological and bleeding disorders. In addition, the rise in geriatric population who are more prone to disorders. For instance, as per the statistics published by the National Institute of Health (NIH), around 23.5 million people in U.S. alone suffer from autoimmune disease thereby leading to increasing need of developing treatment procedures and devices.
Besides, the increasing investments in research and development programs by the biotechnology and pharmaceutical companies is likely to boost the growth of the market. The ongoing research and development in the plasma protein segment are expected to drive its use through multiple applications. The extending use of therapeutic protein drugs in the treatment of a broad range of clinical symptoms are likely to offer numerous growth opportunities for plasma protein therapeutics market in forthcoming years. On the downside, lack of reimbursement and stringent regulation are likely to hamper the market growth to some extent.
The report analyses the global plasma protein therapeutic market based on product, application, and geography.
The various commercially available plasma protein therapeutic products Albumin, Immunoglobulin, plasma-derived factor VIII. Albumin is globular protein found in blood plasma. Serum albumin is the most abundant plasma protein, constituting around 50% of human plasma protein. Albumin is obtained from plasma fractionation process where human serum albumin and bovine serum albumin is most widely used. The albumin segment is expected to grow at significant pace over the forecast period driven by improved diagnosis of hypoalbuminemia caused by liver cirrhosis and hepatitis B. High demand and usage in China, which is the largest market for albumin, is anticipated to further fuel the growth.
Plasma protein therapeutics finds application in Hemophilia, Primary Immunodeficiency Diseases (PID), Idiopathic Thrombocytopenic Purpura (ITP), etc. Primary immunodeficiency diseases includes more than 200 rare, chronic diseases that result from a defect in the immune system. Primary immune deficiency diseases (PIDDs) are rare, genetic disorders that impair the immune system. Without a functional immune response, people with PIDDs may be subject to chronic, debilitating infections, such as Epstein-Barr virus (EBV), which can increase the risk of developing cancer. The PID segment is likely grow at a significant pace owing to the growing expansion of clinical applications for immunoglobulins, and high treatment costs etc.
In terms of region, the plasma protein therapeutics market is studied for the key regions including North America, Europe, Asia Pacific, and Rest of the World. North America region occupied for the largest market share if global plasma protein therapeutic market attributed to presence of large patient base and availability of well-developed infrastructure for storing and maintaining high-quality source plasma are major factors driving the growth of the market. On the other hand, Asia Pacific is likely to grow at a fastest pace over the forecast period owing to increased adoption of novel therapeutics, rising disease prevalence and high R&D investment serve as high growth drivers.
Key competitors of this market include Baxter International, Biotest, CSL Behring, GRIFOLS, S.A., Kedrion Octapharma USA, Inc., Shire Plc and China Biologics among others.
June 2016: Shire Plc acquired Baxalta. Shire acquired Baxalta’s product portfolio and a strong pipeline for the treatment of rare diseases
August 2018: Grifols S.A. acquired 24 plasma donor centers in the U.S. These are operated by Biotest AG
The report analyses the global plasma protein therapeutic market based on product, application, and geography. The various commercially available plasma protein therapeutic products Albumin, Immunoglobulin, plasma-derived factor VIII. Plasma protein therapeutics finds application in Hemophilia, Primary Immunodeficiency Diseases (PID), Idiopathic Thrombocytopenic Purpura (ITP), etc. In terms of region, the plasma protein therapeutics market is studied for the key regions including North America, Europe, Asia Pacific, and Rest of the World. Key competitors of this market include Baxter International, Biotest, CSL Behring, GRIFOLS, S.A., Kedrion Octapharma USA, Inc., Shire Plc and China Biologics among others.
Why to buy this Report: